Biostar Pharmaceuticals, Inc. (BSPM)

[GorillaGorilla]

That sounds about what I would say...

As long as they get near enough to their estimate that's fine - within a million or 2. It's not like were priced for perfection.

Then the auditor and the cash flow remains strong (maybe Q1 may be better for cash after Q4's ramp-up?). And they use their cash wisely - show they are not another Chinese firm that just dilutes.

Approval of Zushima is probably out of their hands?

I think it's all going to be sector driven - but this could be more transparent than most. Should explain what happened to that herb project. Now, can we get them to be as shareholder friendly as CCME!

rich